Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical O... by Nicola J. Nasser, Kai Sun, Karen M. Scanlon, Mark V. Mishra, Jason K. Molitoris

Get full text

Patient preferences for reducing bowel adverse events following prostate radiotherapy. by Mark V Mishra, Winter Maxwell Thayer, Ellen Janssen, Bradford Hoppe, Caitlin Eggleston, John F P Bridges

Get full text

Online advertising and marketing claims by providers of proton beam therapy: are they guideline-based? by Mark T. Corkum, Wei Liu, David A. Palma, Glenn S. Bauman, Robert E. Dinniwell, Andrew Warner, Mark V. Mishra, Alexander V. Louie

Get full text

Identifying barriers to patient acceptance of active surveillance: content analysis of online patient communications. by Mark V Mishra, Michele Bennett, Armon Vincent, Olivia T Lee, Costas D Lallas, Edouard J Trabulsi, Leonard G Gomella, Adam P Dicker, Timothy N Showalter

Get full text

Correction: Identifying Barriers to Patient Acceptance of Active Surveillance: Content Analysis of Online Patient Communications. by Mark V. Mishra, Michele Bennett, Armon Vincent, Olivia T. Lee, Costas D. Lallas, Edouard J. Trabulsi, Leonard G. Gomella, Adam P. Dicker, Timothy N. Showalter

Get full text

Proton beam therapy delivered using pencil beam scanning vs. passive scattering/uniform scanning for localized prostate cancer: Comparative toxicity analysis of PCG 001-09 by Mark V. Mishra, Rahul Khairnar, Søren M. Bentzen, Gary Larson, Henry Tsai, Christopher Sinesi, Carlos Vargas, George Laramore, Carl Rossi, Lane Rosen, Mingyao Zhu, William Hartsell

Get full text

Treatment interruptions affect biochemical failure rates in prostate cancer patients treated with proton beam therapy: Report from the multi-institutional proton collaborative grou... by James E. Han, John Chang, Lane Rosen, William Hartsell, Henry Tsai, Jonathan Chen, Mark V. Mishra, Daniel Krauss, J. Isabelle Choi, Charles B. Simone, Shaakir Hasan

Get full text

Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09 by Mark V. Mishra, Rahul Khairnar, Søren M. Bentzen, Gary Larson, Henry Tsai, Christopher Sinesi, Carlos Vargas, George Laramore, Carl Rossi, Lane Rosen, Kai Sun, William Hartsell

Get full text

Quality of Life and Cognitive Function Evaluations and Interventions for Patients with Brain Metastases in the Radiation Oncology Clinic by Jennifer K. Matsui, Haley K. Perlow, Cyril Baiyee, Alex R. Ritter, Mark V. Mishra, Joseph A. Bovi, Vinai Gondi, Paul D. Brown, Ashlee R. Loughan, Heather E. Leeper, Erica Dawson, Joshua D. Palmer

Get full text

Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases by Emily S. Kowalski, Jill S. Remick, Kai Sun, Gregory S. Alexander, Rahul Khairnar, Emily Morse, Hua-Ren Cherng, Lars J. Berg, Yannick Poirier, Narottam Lamichhane, Stewart Becker, Shifeng Chen, Jason K. Molitoris, Young Kwok, William F. Regine, Mark V. Mishra

Get full text

A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis by Jill S. Remick, Emily Kowalski, Rahul Khairnar, Kai Sun, Emily Morse, Hua-Ren R. Cherng, Yannick Poirier, Narottam Lamichhane, Stewart J. Becker, Shifeng Chen, Akshar N. Patel, Young Kwok, Elizabeth Nichols, Pranshu Mohindra, Graeme F. Woodworth, William F. Regine, Mark V. Mishra

Get full text

Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry by Ali M. Saeed, MD, PhD, Rahul Khairnar, PhD, Ankur M. Sharma, MD, Gary L. Larson, MD, Henry K. Tsai, MD, Chiachien J. Wang, MD, PhD, Lia M. Halasz, MD, Prakash Chinnaiyan, MD, Carlos E. Vargas, MD, Mark V. Mishra, MD

Get full text

Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. by Rahul Khairnar, Stephanie L Pugh, Howard M Sandler, W Robert Lee, Ester Villalonga Olives, C Daniel Mullins, Francis B Palumbo, Deborah W Bruner, Fadia T Shaya, Soren M Bentzen, Amit B Shah, Shawn C Malone, Jeff M Michalski, Ian S Dayes, Samantha A Seaward, Michele Albert, Adam D Currey, Thomas M Pisansky, Yuhchyau Chen, Eric M Horwitz, Albert S DeNittis, Felix Y Feng, Mark V Mishra

Get full text

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities by Canhua Xiao, PhD, Jennifer Moughan, MS, Benjamin Movsas, MD, Andre A. Konski, MD, Gerald E. Hanks, MD, James D. Cox, MD, Mack Roach, III, MD, Kenneth L. Zeitzer, MD, Colleen A. Lawton, MD, Christopher A. Peters, MD, Seth A. Rosenthal, MD, I.-Chow Joe Hsu, MD, Eric M. Horwitz, MD, Mark V. Mishra, MD, Jeff M. Michalski, MD, Matthew B. Parliament, MD, David P. D'Souza, MD, Stephanie L. Pugh, PhD, Deborah W. Bruner, PhD

Get full text

Consensus Statement on Proton Therapy for Prostate Cancer by Curtis M. Bryant, MD, MPH, Randal H. Henderson, MD, MBA, R. Charles Nichols, MD, William M. Mendenhall, MD, Bradford S. Hoppe, MD, MPH, Carlos E. Vargas, MD, Thomas B. Daniels, MD, C. Richard Choo, MD, Rahul R. Parikh, MD, Huan Giap, MD, PhD, Jerry D. Slater, MD, Neha Vapiwala, MD, William Barrett, MD, Akash Nanda, MD, PhD, Mark V. Mishra, MD, Seungtaek Choi, MD, Jay J. Liao, MD, Nancy P. Mendenhall, MD, the Genitourinary Subcommittee of the Particle Therapy Co-Operative Group

Get full text